Moderna (NASDAQ: MRNA) has taken center stage in the race to develop a coronavirus vaccine. In March, the clinical-stage biotech company became the first to bring a vaccine into human trials. Since then, management has reported encouraging trial data that allowed it to move on t
Want to know more on 3 Reasons to Buy Moderna Now click here go to market news source.
Market news summary from Nasdaq Market News.
Author: The Motley Fool